Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC68030 FAK-IN-7 FAK-IN-7 Chemical Structure
  3. GC64836 Famitinib Famitinib (SHR1020), an orally active multi-targeted kinase inhibitor, inhibits the activity of c-kit, VEGFR-2 and PDGFRβ with IC50 values of 2.3 nM, 4.7 nM and 6.6 nM, respectively. Famitinib exerts powerful antitumor activity in human gastric cancer cells and xenografts. Famitinib triggers apoptosis. Famitinib Chemical Structure
  4. GC38437 Fangchinoline An alkaloid with diverse biological activities Fangchinoline Chemical Structure
  5. GC63395 FGFR-IN-1 FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219). FGFR-IN-1 Chemical Structure
  6. GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity. FGFR1/DDR2 inhibitor 1 Chemical Structure
  7. GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively. FGFR2-IN-2 Chemical Structure
  8. GC65992 FGFR2-IN-3 FGFR2-IN-3 is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 Chemical Structure
  9. GC65991 FGFR2-IN-3 hydrochloride FGFR2-IN-3 hydrochloride is an orally active selective inhibitor of FGFR2. FGFR2-IN-3 hydrochloride Chemical Structure
  10. GC19155 FGFR4-IN-1 FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM. FGFR4-IN-1 Chemical Structure
  11. GC62602 FGFR4-IN-5 FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research. FGFR4-IN-5 Chemical Structure
  12. GC50051 FIIN 1 hydrochloride FIIN 1 hydrochloride is a potent, irreversible, selective FGFR inhibitor. FIIN 1 hydrochloride binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN 1 hydrochloride are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively. FIIN 1 hydrochloride Chemical Structure
  13. GC17323 FIIN-2 Irreversible inhibitor of FGFR FIIN-2 Chemical Structure
  14. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3 Chemical Structure
  15. GC47350 Finasteride-d9 An internal standard for the quantification of finasteride Finasteride-d9 Chemical Structure
  16. GC14807 Fingolimod(FTY720) Fingolimod (FTY720) HCl (FTY720), an analog of sphingosine, is a potent sphingosine 1-phosphate (S1P) receptors modulator. Fingolimod(FTY720) Chemical Structure
  17. GC43676 FLT3 Inhibitor III FLT3 Inhibitor III is a potent inhibitor of Fms-like tyrosine kinase 3 (FLT3; IC50 = 50 nM). FLT3 Inhibitor III Chemical Structure
  18. GC32968 FLT3-IN-1 FLT3-IN-1 Chemical Structure
  19. GC33242 FLT3-IN-1 Succinate FLT3-IN-1 Succinate Chemical Structure
  20. GC63936 FLT3-IN-10 FLT3-IN-10 (compound 7c) is a potent inhibitor of FMS-like tyrosine kinase 3 (FLT3). FLT3-IN-10 has the potential for the treatment of FLT3-mutated acute myeloid leukemia (AML). FLT3-IN-10 Chemical Structure
  21. GC65984 FLT3-IN-16 FLT3-IN-16 is a potent FLT3 inhibitor with an IC50 of 1.1 μM. FLT3-IN-16 can be used for researching acute myeloid leukemia. FLT3-IN-16 Chemical Structure
  22. GC19158 FLT3-IN-2 FLT3-IN-2 is a FLT3 inhibitor with IC50 of < 1 uM, detailed information refer to WO 2012158957 A2 and WO 2007013896. FLT3-IN-2 Chemical Structure
  23. GC19772 FLT3-IN-3

    FLT3-IN-3 is a potent FLT3 inhibitor with IC50s of 13 and 8 nM for FLT3 WT and FLT3 D835Y, respectively.

     FLT3-IN-3 Chemical Structure
  24. GC36055 FLT3-IN-4 FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC50=7 nM) inhibitor for treating acute myelogenous leukemia. FLT3-IN-4 Chemical Structure
  25. GC36056 FLT3-IN-6 FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC50 of 1.336 nM. FLT3-IN-6 Chemical Structure
  26. GC32867 Flumatinib (HHGV678) Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678) Chemical Structure
  27. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate Chemical Structure
  28. GC33049 FN-1501 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. FN-1501 Chemical Structure
  29. GC15735 Foretinib (GSK1363089) Foretinib (GSK1363089) is a multi-target tyrosine kinase inhibitor with IC50s of 0.4 nM and 0.9 nM for Met and KDR. Foretinib (GSK1363089) Chemical Structure
  30. GN10527 Formononetin Formononetin Chemical Structure
  31. GC64708 Fosgonimeton Fosgonimeton Chemical Structure
  32. GC11044 Fostamatinib (R788) Fostamatinib (R788) (R788) is the oral prodrug of the active compound R406. Fostamatinib (R788) Chemical Structure
  33. GC10355 Fruquintinib(HMPL-013) Fruquintinib(HMPL-013) (HMPL-013) is a highly potent and selective VEGFR 1/2/3 inhibitor with IC50s of 33, 0.35, and 35 nM, respectively. Fruquintinib(HMPL-013) Chemical Structure
  34. GN10540 Fumalic acid Fumalic acid Chemical Structure
  35. GC12178 G-749 FLT3 inhibitor G-749 Chemical Structure
  36. GC47392 Ganglioside GM1 Mixture (ovine) (ammonium salt) A mixture of ganglioside GM1 Ganglioside GM1 Mixture (ovine) (ammonium salt) Chemical Structure
  37. GC43732 Ganglioside GM3 Mixture (sodium salt) Ganglioside GM3 is a monosialoganglioside that demonstrates antiproliferative and proapoptotic effects in tumor cells by modulating cell adhesion, proliferation, and differentiation. Ganglioside GM3 Mixture (sodium salt) Chemical Structure
  38. GA21893 Gastric Inhibitory Polypeptide (1-30) amide (porcine) Gastric Inhibitory Polypeptide (1-30) amide (porcine) is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). Gastric Inhibitory Polypeptide (1-30) amide (porcine) Chemical Structure
  39. GA21894 Gastric Inhibitory Polypeptide (3-42) (human) Gastric Inhibitory Polypeptide (3-42) (human) acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo. Gastric Inhibitory Polypeptide (3-42) (human) Chemical Structure
  40. GC16737 Gefitinib (ZD1839)

    Gefitinib (ZD1839), is a potent EGFR-TKI (EGFR tyrosine kinase inhibitor)

     Gefitinib (ZD1839) Chemical Structure
  41. GC60868 Gefitinib D8 Gefitinib D8 (ZD1839 D8) is a deuterium labeled Gefitinib. Gefitinib is an EGFR tyrosine kinase inhibitor, with IC50 of 2-37 nM in NR6wtEGFR cells. Gefitinib D8 Chemical Structure
  42. GC14295 Gefitinib hydrochloride An EGFR inhibitor Gefitinib hydrochloride Chemical Structure
  43. GC19509 Gefitinib-based PROTAC 3 A VHL-recruiting PROTAC Gefitinib-based PROTAC 3 Chemical Structure
  44. GC47395 Gefitinib-d6 An internal standard for the quantification of gefitinib Gefitinib-d6 Chemical Structure
  45. GC65478 Gemnelatinib Gemnelatinib is a tyrosine kinase inhibitor (WO2018077227, implementation example 1). Gemnelatinib can be used for the research of cancer. Gemnelatinib Chemical Structure
  46. GC14102 Genistein

    Genistein is an isoflavone belonging to the flavonoid group of compounds and is found in a number of plants.

     Genistein Chemical Structure
  47. GC47398 Genistein-d4 An internal standard for the quantification of genistein Genistein-d4 Chemical Structure
  48. GC31842 GENZ-882706 (RA03546849) GENZ-882706 (RA03546849) is a potent colony stimulating factor-1 receptor (CSF-1R) Inhibitor extracted from patent WO 2017015267A1. GENZ-882706 (RA03546849) Chemical Structure
  49. GC30295 GENZ-882706(Raceme) (GENZ-882706 racemate) GENZ-882706(Raceme) (GENZ-882706 racemate) is the racemate of GENZ-882706. GENZ-882706(Raceme) (GENZ-882706 racemate) Chemical Structure
  50. GC62633 GGTI-2154 GGTI-2154 is a potent and selective inhibitor of geranylgeranyltransferase I (GGTase I), with an IC50 of 21 nM. GGTI-2154 shows more than 200-fold selectivity for GGTase I over FTase (IC50=5600 nM). GGTI-2154 can be used for the research of cancer. GGTI-2154 Chemical Structure
  51. GC19482 Gilteritinib

    Gilteritinib (ASP2215, Xospata) for relapsed and /or refractory AML (R/R AML).

     Gilteritinib Chemical Structure
  52. GC36135 Gilteritinib hemifumarate Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC50 of 0.29 nM/0.73 nM, respectively. Gilteritinib hemifumarate Chemical Structure
  53. GN10156 Ginsenoside Rb1 Ginsenoside Rb1 Chemical Structure
  54. GC31706 Ginsenoside Rg5 A ginsenoside with diverse biological activities Ginsenoside Rg5 Chemical Structure
  55. GC61569 GIP (1-30) amide, porcine TFA GIP (1-30) amide, porcine TFA is a full glucose-dependent insulinotropic polypeptide (GIP) receptor agonist with high affinity equal to native GIP(1-42). GIP (1-30) amide, porcine TFA Chemical Structure
  56. GC60175 GIP (1-30) amide,Human acetate GIP (1-30) amide,human acetate is a glucose-dependent insulinotropic polypeptide (GIP) fragment. GIP (1-30) amide,Human acetate Chemical Structure
  57. GC61741 GIP, human TFA GIP, human TFA, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human TFA Chemical Structure
  58. GC19166 Glesatinib hydrochloride Glesatinib hydrochloride is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered. Glesatinib hydrochloride Chemical Structure
  59. GC64947 Glumetinib Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity. Glumetinib Chemical Structure
  60. GC36167 GMB-475 GMB-475 is a degrader of BCR-ABL1 tyrosine kinase based on PROTAC, overcoming BCR-ABL1-dependent drug resistance. GMB-475 targets BCR-ABL1 protein and recruits the E3 ligase Von Hippel Lindau (VHL), resulting in ubiquitination and subsequent degradation of the oncogenic fusion protein. GMB-475 Chemical Structure
  61. GC31871 GNE-0946 GNE-0946 is a potent and selective RORγ( RORc) agonist with an EC50 value of 4 nM for HEK-293 cell. GNE-0946 Chemical Structure
  62. GC32053 GNE-4997 GNE-4997 is a potent and selective interleukin-2-inducible T-cell kinase (ITK) inhibitor with a Ki of 0.09 nM, and the correlation between the basicity of solubilizing elements in GNE-4997 and off-target antiproliferative effects reduces cytotoxicity. GNE-4997 Chemical Structure
  63. GC33882 GNE-6468 GNE-6468 is a highly potent and selective RORγ (RORc) inverse agonist with an EC50 value of 13 nM for HEK-293 cell. GNE-6468 Chemical Structure
  64. GC12121 GNE-7915 Potent and selective LRRK2 inhibitor GNE-7915 Chemical Structure
  65. GC36171 GNE-7915 tosylate GNE-7915 tosylate is a potent, selective and brain-penetrant inhibitor of LRRK2 with an IC50 of 9 nM. GNE-7915 tosylate Chemical Structure
  66. GC13868 GNE-9605 LRRK2 inhibitor, brain-penetrant, potent and selective GNE-9605 Chemical Structure
  67. GC15196 GNE0877 Potent and selective LRRK2 inhibitor GNE0877 Chemical Structure
  68. GC10858 GNF 2 Bcr-Abl inhibitor GNF 2 Chemical Structure
  69. GC15079 GNF 5 Bcr-Abl inhibitor GNF 5 Chemical Structure
  70. GC16343 GNF-5837 Pan-Trk inhibitor GNF-5837 Chemical Structure
  71. GC10607 GNF-7

    Type II Bcr-Abl inhibitor

     GNF-7 Chemical Structure
  72. GC64724 GNF2133 GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively. GNF2133 Chemical Structure
  73. GC64725 GNF2133 hydrochloride GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 ?M for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride Chemical Structure
  74. GC38787 GNF4877 GNF4877 is a potent DYRK1A and GSK3β inhibitor with IC50s of 6?nM and 16?nM, respectively, which leads to blockade of nuclear factor of activated T-cells (NFATc) nuclear export and increased β-cell proliferation (EC50 of 0.66?μM for mouse β (R7T1) cells). GNF4877 Chemical Structure
  75. GC17715 Golvatinib (E7050) Golvatinib (E7050) (E-7050) is a potent dual inhibitor of both c-Met and VEGFR2 kinases with IC50s of 14 and 16 nM, respectively. Golvatinib (E7050) Chemical Structure
  76. GC16430 GS-9973 GS-9973 (GS-9973) is an orally bioavailable, selective Syk inhibitor with an IC50 of 7.7 nM. GS-9973 Chemical Structure
  77. GC50429 GSK 143 Syk inhibitor GSK 143 Chemical Structure
  78. GC50156 GSK 2250665A Itk inhibitor GSK 2250665A Chemical Structure
  79. GC36194 GSK-626616 GSK-626616 is a potent, orally bioavailable inhibitor of DYRK3 (IC50=0.7 nM). GSK-626616 Chemical Structure
  80. GC68447 GSK143 dihydrochloride GSK143 dihydrochloride Chemical Structure
  81. GC12273 GSK1838705A IGF-IR/IR/ALK inhibitor, ATP-competitive GSK1838705A Chemical Structure
  82. GC17612 GSK1904529A Selective IGF-1R/IR inhibitor GSK1904529A Chemical Structure
  83. GC64888 GSK215 GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC50 of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect. GSK215 Chemical Structure
  84. GC19179 GSK2256098 GSK2256098 is a selective FAK kinase inhibitor, which inhibits growth and survival of pancreatic ductal adenocarcinoma cells. GSK2256098 Chemical Structure
  85. GC18049 GSK2578215A LRRK2 inhibitor GSK2578215A Chemical Structure
  86. GC64889 GSK2646264 GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC50 of 7.1. GSK2646264 Chemical Structure
  87. GC13905 GSK2981278 RORγ-selective inverse agonist GSK2981278 Chemical Structure
  88. GC18492 GSK3179106 A RET kinase inhibitor GSK3179106 Chemical Structure
  89. GC18591 GSK805 GSK805 is a potent, orally bioavailable retinoid-related orphan receptor gamma t (RORγt) inverse agonist that interacts with the receptor's putative ligand binding domain without exerting significant effects on DNA binding. GSK805 Chemical Structure
  90. GC64875 Gunagratinib Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib Chemical Structure
  91. GC33041 Gusacitinib (ASN-002) Gusacitinib (ASN-002) (ASN-002) is an orally active and potent dual inhibitor of spleen tyrosine kinase (SYK) and janus kinase (JAK) with IC50 values of 5-46 nM. Gusacitinib (ASN-002) has anti-cancer activity in both solid and hematological tumor types. Gusacitinib (ASN-002) Chemical Structure
  92. GC15927 GW 583340 dihydrochloride dual EGFR/ErbB2 tyrosine kinase inhibitor GW 583340 dihydrochloride Chemical Structure
  93. GC17286 GW2580 CFMS kinase/CSF-1R inhibitor,selective and ATP-competitive GW2580 Chemical Structure
  94. GC14123 GW441756 TrkA inhibitor,potent and selective GW441756 Chemical Structure
  95. GC36203 GW806742X GW806742X, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X Chemical Structure
  96. GC61454 GW806742X hydrochloride GW806742X hydrochloride, an ATP mimetic and a potent MLKL (Mixed Lineage Kinase Domain-Like protein) inhibitor, binds the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X hydrochloride has activity against VEGFR2 (IC50=2 nM). GW806742X hydrochloride retards MLKL membrane translocation and inhibits necroptosis. GW806742X hydrochloride Chemical Structure
  97. GC10915 GZD824 Olverembatinib (GZD824) dimesylate is a potent and orally active pan-Bcr-Abl inhibitor. GZD824 potently inhibits a broad spectrum of Bcr-Abl mutants. GZD824 strongly inhibits native Bcr-Abl and Bcr-AblT315I with IC50s of 0.34 nM and 0.68 nM, respectively. GZD824 has antitumor activity. GZD824 Chemical Structure
  98. GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 Chemical Structure
  99. GC62453 GZD856 formic GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 formic Chemical Structure
  100. GC17923 H-7 dihydrochloride H-7 dihydrochloride is a potent PKC (protein kinase C) inhibitor. At 100 μM, H-7 dihydrochloride completely inhibits both TPA (skin tumour promoter, 12-O-tetradecanoylphorbol-13-acetate) and phospholipase C-induced ODC (ornithine decarboxylase). H-7 dihydrochloride Chemical Structure
  101. GC11420 H-9 dihydrochloride Protein kinase inhibitor H-9 dihydrochloride Chemical Structure

Items 401 to 500 of 1115 total

per page
  2. 3
  3. 4
  4. 5
  5. 6
  6. 7

Set Descending Direction